Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
Daiichi Sankyo2024-03-25 09:37:57CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed-dose
-
Daiichi Sankyo2024-01-03 13:44:14Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including
-
Daiichi Sankyo2022-12-08 10:41:45Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative
-
Daiichi Sankyo2022-09-06 16:43:43Latest simulation analyses from the SANTORINI registry indicates that adding bempedoic acid in the lipid
-
Daiichi Sankyo2022-09-06 16:40:26New data further strengthens important role of LIXIANA® (edoxaban) in managing complex patient populations
-
Daiichi Sankyo2022-05-24 17:09:00Daiichi Sankyo Europe highlights need to address the perception and classification of CVD risk with data
-
Daiichi Sankyo2022-05-24 17:15:36People Who Have Had COVID-19 More Likely to Develop Cardiovascular Disease: New Report Highlights the Need to
-
Daiichi Sankyo2021-04-26 09:44:48New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with
-
Daiichi Sankyo2021-02-02 11:33:17First-in-class cholesterol-lowering treatment NILEMDO® ▼ (bempedoic acid) tablet and its combination with
-
Daiichi Sankyo2020-11-16 10:51:13Pooled analyses show NILEMDO®▼ significantly lowers cholesterol in different subgroups in Phase 3 data